No Effect of NSAID Use on Efficacy of Zoledronate: A Post Hoc Analysis of a Randomized Trial in Osteopenic Older Women.
ANTIRESORPTIVES
BISPHOSPHONATES
OSTEOPOROSIS
Journal
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
ISSN: 1523-4681
Titre abrégé: J Bone Miner Res
Pays: United States
ID NLM: 8610640
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
revised:
27
06
2023
received:
01
02
2023
accepted:
15
07
2023
pubmed:
21
7
2023
medline:
21
7
2023
entrez:
21
7
2023
Statut:
ppublish
Résumé
Bisphosphonates are widely used for the prevention and treatment of osteoporosis. Nonsteroidal anti-inflammatory drugs (NSAIDs) are also widely used among the older population group at high risk of fractures. NSAIDs have been shown to impact on bone turnover, and a recent reanalysis of a clinical trial of clodronate found that NSAID use at baseline abrogated any effect of clodronate on either bone density (BMD) or fracture risk. To determine whether NSAIDs influence the efficacy of other bisphosphonates, we have reanalyzed our 6-year randomized controlled trial of zoledronate in 2000 osteopenic postmenopausal women. NSAID use was reported at baseline in 38% of the cohort and anytime use was reported by 65%. The evolution of the zoledronate effects on BMD were almost identical whether or not women were using NSAIDs at baseline and were significant in both subgroups at all BMD sites (p < 0.0001). The significant reduction in the risk of fracture in those allocated to zoledronate (p < 0.0001) showed no interaction with baseline use of NSAIDs (p = 0.33) nor with NSAID use at any time during the study (p = 0.28). The odds of fracture were significantly reduced in both NSAID users and nonusers. We conclude that the present analysis provides no support for the suggestion that NSAIDs interfere with the efficacy of potent bisphosphonates in terms of their effects on bone density or fracture. © 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1415-1421Subventions
Organisme : Health Research Council of New Zealand
Informations de copyright
© 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
Références
Pilotto A, Franceschi M, Leandro G, Di Mario F. NSAID and aspirin use by the elderly in general practice: effect on gastrointestinal symptoms and therapies. Drugs Aging. 2003;20:701-710.
Take I, Kobayashi Y, Yamamoto Y, et al. Prostaglandin E-2 strongly inhibits human osteoclast formation. Endocrinology. 2005;146:5204-5214.
Yoshida K, Oida H, Kobayashi T, et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci USA. 2002;99:4580-4585.
Kaspar D, Hedrich CM, Schmidt C, Liedert A, Claes LE, Ignatius AA. Diclofenac inhibits proliferation and matrix formation of osteoblast cells. Unfallchirurg. 2005;108:18-24.
Lauritzen DB, Balena R, Shea M, et al. Effects of combined prostaglandin and alendronate treatment on the histomorphometry and biomechanical properties of bone in ovariectomized rats. J Bone Miner Res. 1993;8:871-879.
Gerstenfeld LC, Thiede M, Seibert K, et al. Differential inhibition of fracture healing by non-selective and cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs. J Orthop Res. 2003;21:670-675.
Zhang X, Schwarz EM, Young DA, Edward Puzas J, Rosier RN, O'Keefe RJ. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. J Clin Invest. 2002;109:1405-1415.
Bell NH, Hollis BW, Shary JR, et al. Diclofenac sodium inhibits bone resorption in postmenopausal women. Am J Med. 1994;96:349-353.
Richards JB, Joseph L, Schwartzman K, Kreiger N, Tenenhouse A, Goltzman DGAC. The effect of cyclooxygenase-2 inhibitors on bone mineral density: results from the Canadian Multicentre Osteoporosis study. Osteoporos Int. 2006;17:1410-1419.
Bauer DC, Orwoll ES, Fox KM, et al. Aspirin and NSAID use in older women-effect on bone mineral density and fracture risk. J Bone Miner Res. 1996;11:29-35.
Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcif Tissue Int. 2006;79:84-94.
Van Staa TP, Leufkens HGM, Cooper C. Use of nonsteroidal anti-inflammatory drugs and risk of fractures. Bone. 2000;27:563-568.
Borgeat A, Ofner C, Saporito A, Farshad M, Aguirre J. The effect of nonsteroidal anti-inflammatory drugs on bone healing in humans: a qualitative, systematic review. J Clin Anesth. 2018;49:92-100.
Zheng Z, Johansson H, Harvey NC, et al. Potential adverse effect of nonsteroidal anti-inflammatory drugs (NSAIDs) on bisphosphonate efficacy: an exploratory post hoc analysis from a randomized controlled trial of clodronate. J Bone Miner Res. 2022;37:1117-1124.
McCloskey EV, Beneton M, Charlesworth D, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res. 2007;22:135-141.
Reid IR, Horne AM, Mihov B, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med. 2018;379:2407-2416.
Vestergaard P, Hermann P, Jensen JEB, Eiken P, Mosekilde L. Effects of paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and opioids on bone mineral density and risk of fracture: results of the Danish Osteoporosis Prevention Study (DOPS). Osteoporos Int. 2012;23:1255-1265.
Chuang PY, Shen SH, Yang TY, Huang TW, Huang KC. Non-steroidal anti-inflammatory drugs and the risk of a second hip fracture: a propensity-score matching study. BMC Musculoskelet Disord. 2016;17:201.
Rossini M, Viapiana O, Adami S, et al. Medication use before and after hip fracture: a population-based cohort and case-control study. Drugs Aging. 2014;31:547-553.